Search | Clinical Trials Finder

Conditions: Invasive Fungal Infections
Interventions: Olorofim; Drug
Lead sponsor: F2G Biotech GmbH; Industry
Eligibility: 16 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 14
States / cities: Bakersfield, California • Sacramento, California • San Diego, California + 11 more

Conditions: Allergic Bronchopulmonary Aspergillosis
Interventions: PUR1900, Placebo; Combination Product
Lead sponsor: Pulmatrix Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more

Conditions: Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infection, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interferon gamma, voriconazole; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Bethesda, Maryland

Conditions: Aspergillosis
Interventions: voriconazole, anidulafungin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Atlanta, Georgia • Detroit, Michigan • Fort Worth, Texas

Conditions: Allergic Bronchopulmonary Aspergillosis
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more

Conditions: Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Conditions: Mycoses
Interventions: itraconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acquired Immunodeficiency Syndrome, Aspergillosis, HIV Infections, Immunologic Deficiency Syndromes, Neutropenia
Interventions: Voriconazole, Amphotericin B; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions: cholecalciferol (Vitamin D3); Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Aspergillosis
Interventions: Opelconazole, Standard of Care; Drug
Lead sponsor: Pulmocide Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Cystic Fibrosis
Interventions: Placebo, QBW251; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Aspergillosis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Aspergillosis, Candidemia
Interventions: anidulafungin and voriconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Aspergillosis
Interventions: Voriconazole, micafungin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Invasive Mucormycosis, Invasive Aspergillosis
Interventions: Isavuconazonium sulfate; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 1 more

Conditions: Covid19, Aspergillosis, Fungal Infection
Interventions: Observation to monitor patients for these infections; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Invasive Aspergillosis
Interventions: Posaconazole IV, Posaconazole PFS, Posaconazole tablet; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Orange, California • San Diego, California • Chicago, Illinois + 1 more

Conditions: Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions: Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B; Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more

Conditions: Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aspergillosis, Lung Diseases, Fungal
Interventions: Itraconazole oral solution; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Invasive Fungal Infections
Interventions: fosmanogepix; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Duarte, California • Durham, North Carolina

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive
Interventions: Isavuconazonium Injection [Cresemba], Placebo; Drug
Lead sponsor: Jeffrey Jenks, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Orange, California • Sacramento, California • San Diego, California

Search by objective public record fields.

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis